Pimavanserin effective for depression in parkinson disease, major depressive disorder
Pimavanserin, a selective 5-HT2A receptor antagonist/inverse agonist, was reported to successfully treat depression among patients with Parkinson disease (PD) and major depressive disorder (MDD). These findings, from a pooled analysis of 2 trials, were presented during Psych Congress 2020 Virtual Experience, held online from September 11 to 13, 2020.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063